RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous Non-Small Cell Lung Cancer after failure of platinum-based chemotherapy in Brazil - RACE-2L

Inclusion Criteria

• • Confirmed diagnosis of patients with non-squamous NSCLC stage IIIB/IIIC not eligible for curative-intent therapies or stage IV/M1 (a/m NSCLC) with or without actionable genomic mutations (i.e., EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, HER-2)
• • Aged at least 18 years at first diagnosis of a/m NSCLC
• • For the AGA subgroup, having received platinum-based chemotherapy, having received at least one target approved therapy.
• • For the non_AGA subgroup,should have received either sequential or concurrent use of ICI and PTC)
• • Patient must have received at least line of therapy of an active agent after failing PTC.